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ABSTRACT
The aim of this paper is to present the most relevant 
clinical applications of positron emission tomography/ 
/computed tomography, scintigraphy and single pho-
ton emission tomography with different radiotracers 
allowing to visualize e.g. glucose metabolism, amino 
acids metabolism, receptor density or inflammation 
and infections in diabetology. (Clin Diabetol 2019; 8, 
6: 303–309)
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Introduction
According to data provided by the Central Statisti-
cal Office, it is estimated that in Poland there are more 
than 2.1 million people with both diabetes types and 
in 2016, there were 659 new cases and 2,517 407 
medical consultations provided in diabetology clinics 
[1]. Nuclear medicine uses the properties of radioac-
tive isotopes to visualize the various physiological 
processes taking place in the body. Positron emission 
tomography/computed tomography (PET/CT) and 
scintigraphy, the extension of which is single photon 
emission tomography/computed tomography (SPECT/ 
/CT) and three-phase scintigraphy (allowing to visualize 
the blood flow, tissue and bone phase of the examined 
area) are now the basic imaging methods used in nu-
clear medicine. In addition nuclear medicine techniques 
have been used in oncology (for example to determine 
the severity of the disease or to assess the response 
to the applied treatment), cardiology (for example for 
assessing myocardial perfusion or myocardial viability) 
and in neurology (i.e. for imaging a brain tumors and 
in neurodegenerative disease) [2]. 
The aim of this paper is to present the most impor-
tant applications of PET/CT, SPECT/CT and three-phase 
scintigraphy and also to show the future directions 
which might have implications on management in 
diabetic patients.
Scintigraphy
Scintigraphy in an imaging technique that uses 
a gamma camera consisting of one or more detector 
heads to create a functional 3D distribution of a photon 
emitter radionuclide from the patient’s body. The raw 
data for the reconstruction of spatial distribution are 
acquired as a series of discrete planar images at multi-
ple angles over the longitudinal axis of the patient [2]. 
The main elements of the detector head are 
a collimator, a scintillation crystal and a photomul-
tiplier (Fig. 1). The collimator creates a radionuclide 
image of the patient on the scintillation crystal, which 
converts gamma rays into light. The light is detected 
by photomultiplier tubes whose digital output is used 
to calculate the spatial coordinates of each scintillation 
event. The computer system is used for processing 
(reconstructing), storing and displaying images [3].
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Whole body scan (WBS) with 99 metatable techne-
tium (99mTc) labelled diphosphonates, e.g. methylene 
diphosphonate (MDP), hydroxyethylidene diphospho-
nate (HEDP) and hydroxymethylene diphosphonate 
(HMDP) are a useful tool for imaging malignant otitis 
externa and scintigraphy with labelled leukocytes, is 
the most commonly used techniques in inflammation 
and infection imaging. Infections in diabetology can 
be divided into frequent and specific ones. Frequent 
infections include: fungal infections, pulmonary tuber-
culosis, pneumonia, bacteremia, urinary tract infec-
tions, renal replacement infections (hemodialysis or 
continuous ambulatory peritoneal dialysis), skin and 
bone infections and diabetic foot infections [4]. Specific 
infections in diabetic patients include nasocerebral 
mucormycosis, malignant otitis external, emphysema, 
and emphysema cholecystitis [5–7].
Diagnosis of diabetic foot
Magnetic resonance imaging (MRI) is the method 
of choice in imaging diabetic foot infection and os-
teomyelitis [8], however, also radioisotope methods, 
including scintigraphy, are beginning to play a signifi-
cant role in the diagnosis of this disease. Three-phase 
scintigraphy allows to obtain additional information on 
the vascularization of the examined area. The first phase 
of the study (blood flow) exposes increased blood circu-
lation around the ongoing inflammatory process, while 
the second phase of the study (tissue phase) evaluates 
the volume of blood in the area. The last part of the 
study is the metabolic phase (delayed phase), which 
illustrates the increased accumulation of the radiotracer 
in the area in which increased osteoblastic activity is 
noted [4]. The image obtained with this technique does 
not allow differential diagnosis of fracture with Charcot 
neuro-osteoartropathy [9] due to low specificity (from 
10–67%, mean 40%) [10], therefore, a modification 
of the study was introduced by adding 4th phase after 
24 hours from radiopharmaceutical administration. 
This is due to the fact that in the osteomyelitis, the 
accumulation of the radiotracer lasts for several hours, 
while in uninfected bones up to 4 hours. If in phase 4 
the target-to-background ratio increases, this is the 
sufficient basis for confirmation of osteomyelitis [11], 
while the ratio of target-to-background with a point of 
1.06 with 82% sensitivity and 92% specificity allows to 
diagnose osteoarthritis. Compared to standard three-
phase bone scintigraphy, adding 4th phase increases 
the specificity of the method to 87% [12]. 
A significant improvement in the diagnosis of os-
teoarthritis has been observed with the use of labeled 
leukocytes (in vitro or in vivo), which show increased 
accumulation in inflammation. One of the most com-
monly used ligands labeled with 99mTc is hexamethyl-
propylene amine oxime (HMPAO). The sensitivity and 
specificity of a static scintigraphic study using 99mTc-
-HMPAO is 90–93% and 86–100% respectively [13, 
14], while the sensitivity and specificity for three-phase 
scintigraphy with 99mTc-HMPAO is 92.6% and 97.6% 
respectively in bone inflammation diagnosis [15].
Myocardial ischemia and myocardial infarction are 
much more common in patients with diabetes due to 
the asymptomatic course of cardiac complications in 
these patients, therefore, an appropriate strategy can 
have a key impact in the diagnosis of silent ischemia. 
Methoxyisobutylisonitrile (MIBI) labeled with 99mTc is 
the most widely used radiotracer for assessing myo-
cardial perfusion. The 99mTc-MIBI-SPECT/CT examina-
tion performed after exercise is characterized by high 
sensitivity and accuracy in the diagnosis of coronary 
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Figure 1. Scheme of a conventional gamma camera used in scintigraphy [3]
Paulina Cegła et al., Nuclear medicine in diabetology
305
heart disease. Authors from the International Atomic 
Energy Agency found that patients with diabetes more 
often suffer from myocardial ischemia and that dia-
betes was an independent factor associated with the 
occurrence of myocardial ischemia in relation to the 
control group. In addition, in people suffering from 
diabetes, myocardial ischemia was more frequent, 
visible in the electrocardiogram (ECG) picture during 
exercise, while no significant differences in detecting 
myocardial ischemia between the group of patients 
and the control group in ECG and 99mTc-MIBI-SPECT/ 
/CT were found [16].
Diabetic gastroparesis
Gastroparesis is defined as a delay in gastric empty-
ing and one of causes is a complication of diabetes mel-
litus [17]. According to various sources diabetic gastro-
paresis is diagnosed in 30–50% of patients in type 1 and 
2 diabetes and is more common in female than in men 
[18]. Diabetic gastroparesis might be divided into two 
types: reversible (when normal gastric motility returns 
after glycemic normalization) and irreversible (when 
after normalization of glycemia there is still incorrect 
gastric motility function). There are several methods 
to measure gastric emptying, however scintigraphy 
with 99mTc is the gold standard. This is a noninvasive 
imaging techniques which involves measuring the rate 
of gastric emptying with the meal (usually 2 slices of 
bread with jam and 2 large eggs with 99mTc). Imaging is 
performed at baseline, 30 minutes, 1 hour, 2 hours and 
4 hours after the meal. The 1 hour postprandial scan 
is use to visualize the rapid gastric emptying while the 
2- and 4-hour scans are used in delayed visualization 
of gastric emptying. Extension of gastric emptying by 
10% over a 4-hour norm in the case of men allows to 
diagnose a diabetic gastroparesis, while in women the 
prolonged time must exceed 25%. Other radionuclide 
methods which allow to measure gastric emptying 
include breath testing utilizes a nonradioactive carbon 
isotope (13C) bound with spirulina or octanoic acid 
which is mixed with eggs, absorbed from small bowel 
and metabolized by the liver. Then it is expelled from 
lungs and measured in exhale breath. Specificity and 
sensitivity of this method is similar to the scintigraphy 
with 99mTc (80% and 86%, respectively), however in 
a patients with concurrent lungs, pancreatic or liver 
disease, this examination might give a false positive 
results. That’s why scintigraphy with 99mTc is the gold 
standard in diagnosis of diabetic gastroparesis [17, 18]. 
Other infections 
In case of malignant otitis external (MOE) 99mTc-
-MDP study is helpful in differential diagnosis from 
simple external otitis by the increased accumulation of 
the radiotracer in the temporal bone and the base of 
the skull. 99mTc bone scan is more sensitive than other 
imaging techniques like CT scans or radiography and 
allows for earlier diagnosis of MOE, because it shows 
functional changes which occur earlier than anatomic 
ones. Additionally, a scintigraphy with gallium 67 has 
been proposed to assess the response to treatment in 
patients with MOE [19].
Diagnosis of kidney diseases with labeled di-
mercaptosuccinic acid 99mTc (99mTc-DMSA) allows to 
determine the distribution of kidney function, the 
focal changes in the parenchyma, to determine the 
shape and position of the kidneys or to assess the 
transplanted kidney. The degree of radiopharmaceutical 
accumulation is dependent on the functional state of 
the proximal tubules and blood flow [20]. In case of 
acute pyelonephritis, there are three types of abnormal 
results: regional, multifocal and the diffused one. As a 
result of scar formation in the course of chronic pyelo-
nephritis, a reduced uptake of the radiopharmaceutical 
(usually in a triangular shape, the base directed towards 
the kidney surface) is observed in the damaged part of 
the kidney parenchyma [21, 22].
Scintigraphy with 99mTc labeled iminodiacetic acid 
(IDA) allows to assess the function of the liver and 
bile ducts and imaging of a gallbladder. Presence of 
gallbladder in 99mTc-IDA scintigraphy suggest cystic 
duct patency and absence — obstruction. This is very 
important imaging method, especially in type 2 diabe-
tes, because allows to differentiate non-alcoholic fatty 
liver disease (NAFDL) with non-alcoholic steatohepatitis 
(NASH), hepatitis and liver cirrhosis. NAFDL is associa-
ted with insulin resistance and obesity which are one 
of the most common causes of type 2 diabetes. The 
most commonly used are 3 ligands: trimetyloacetanilido 
acid (MBrIDA), hepatoiminodiacetic acid (HIDA) and 
diisopropyliminodiacetic acid (DISIDA) [23]. This ima-
ging shows a higher sensitivity compared to ultrasound 
(86% to 48% respectively), while the combination of 
both techniques increases the sensitivity to 90% [24]. 
The secondary function of the 99mTc-IDA examination 
is the liver uptake rate of the radiopharmaceutical (in 
a well-functioning liver within a few minutes a marked 
decrease in radioactivity in the bloodstream and visibili-
ty of the liver parenchyma is noticed) and the rate of 
passage of the radiopharmaceutical from the bile ducts 
to the small intestine (properly functioning gallbladder 
becomes visible between 15 and 30 minutes of the 
study, while at the end of the acquisition the radiophar-
maceutical should be visible in the bowel projection). 
Decreased radiotracer uptake from the bloodstream 
suggests damage to hepatocyte function, delaying bile 
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excretion to the intestines is an evidence of impaired 
bile duct patency, and total intestinal uptake after 24 
hours from radiopharmaceutical administration — on 
arthritis or total obstruction of the bile ducts [22, 23].
Positron emission tomography (PET)
The physics of imaging in positron emission to-
mography (PET) is based on the emission of positrons 
from nuclei with excessive amounts of protons. Posi-
tron moves a short distance in the patient’s tissue and 
annihilates on contact with electron. The effect of the 
annihilation of the electron-positron pair is the genera-
tion of two photons with 511 keV that are emitted in 
opposite directions. Due to the nature of the photon 
pair emission process, a single detector system used 
in SPECT imaging does not provide the appropriate 
geometry for the simultaneous detection of two pho-
tons [24], thus a typical PET scanner consists of many 
rings of scintillation detectors. Due to the registration 
of photon coincidences, a collimator is not required, 
which significantly increases the sensitivity of PET in 
comparison with the gamma camera [2]. When both 
photons from an annihilation are absorbed simulta-
neously (in coincidence) in two opposing detectors, 
a count will be made (Fig. 2). The photon registration 
process looks the same as in the gamma camera. As 
a result of annihilation of positrons of the radionuclide 
with electrons in tissue, the emission of photon pair of 
511 keV in opposite directions takes place. Registration 
of photons on a scintillation crystal within a given time 
interval means coincidence detection. Further process-
ing of the recorded signal using a photomultiplier 
allows to determine the spatial coordinates of each 
count [25]. Using an electronic system consisting of 
a photomultiplier tube and an analog-digital converter, 
an electrical signal from a scintillation in the detector’s 
crystal after interaction with the photon is recorded. 
After the acquisition, first the acquired images are 
corrected for damping and scattering, etc., and then 
processed mathematically to obtain transverse images 
of the layers of the studied area [26].
One of the most commonly used radiopharma-
ceuticals in the PET technique is the fluorine-labeled 
glucose analogue (18F-FDG). Due to the metabolic 
vector used, this radiopharmaceutical, in addition to 
uptake in cells showing increased request/needs for 
glucose (including cancer cells), also accumulates in 
inflammatory lesions. The sensitivity of the 18F-FDG-
-PET/CT study decreases with the increase glucose level 
(should not exceed 200 mg/dL; 11.1 mmol/l), hence 
new, alternative markers for 18F-FDG that can be used 
in diabetic patients, regardless of the level of glucose 
in the blood are needed. 
For neuroendocrine tumors imaging (including 
insulinoma and glucagonoma), which has the prese-
nce of somatostatin receptors, the PET/CT study with 
68Ga-DOTA-peptides is used. Several derivatives of 68Ga-
labeled somatostatin are available, which differ in their 
affinity for various somatostatin receptor subtypes. 
68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE 
and 68Ga-DOTA-LAN they bind to the somatostatin 
receptor subtype 2 (SSTR2), showing different affini-
ty for other receptor subtypes SSTR: 68Ga-DOTA-NOC 
and 68Ga-DOTA-LAN to SSTR 3 and 5, 68Ga-DOTA-TOC 
connects also with SSTR5 (however with less affinity 
than DOTA-NOC), whereas 68Ga-DOTA-TATE shows 
the highest affinity for the SSTR2 receptor among all 
peptides [27, 28].
Figure 2. Schematic diagram of a coincidence [25]
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Another radioisotope used in the diagnosis of 
insulinomas in children and infants is Fluorine-labeled 
dihydroxyphenylalanine (18F-DOPA) [28]. Congenital 
hyperinsulinism is one of the most common causes of 
hypoglycaemia in newborns, among which two his-
tological subtypes are distinguished: diffused (about 
95–98% of cases) and focal one. In half of infants 
requiring pancreatic resection, a curable focal form 
is found, and the performance of the 18F-DOPA-PET/ 
/CT study allows for differential diagnosis of diffused 
and focal forms and the selection of an appropriate 
treatment method. Identification and exact location 
of the lesion in the case of focal hyperinsulinism allow 
resection limited to the focal point leading to a reduc-
tion of postoperative complications in treated children 
including diabetes and pancreatic enzyme substitution 
[29, 30]. 18F-DOPA-PET/CT study diagnose 75–100% 
focal changes [31].
One of the latest developments in nuclear medicine 
is the ability to label glucagon-like peptide-1 receptor 
(GLP-1R) present in insulinoma. It was found that no 
other peptide receptor showed such high levels of ex-
pression in this type of tumors (frequency > 90% and 
density 8.133 dpm/mg tissue) [32]. PET/CT study with 
labeled gal 68 exendin-4 (68Ga-DOTA-exendin-4 PET/CT) 
showed that it is a sensitive diagnostic tool for detect-
ing insulinoma tumors and locating latent tumors [33, 
34]. Sensitivity of 68Ga-DOTA-exendin-4 PET/CT exceeds 
conventional imaging methods (including computed 
tomography, MRI and transesophageal ultrasound) in 
detecting this types of tumors [35].
Future directions
A huge development took place in the production 
of radiopharmaceuticals for imaging bacterial infec-
tions. 64Cu-MAb 1D9, 89Zr-MAb 1D9, 68Ga-UBI29–41, 
m-[18F]-fluoro-PABA, [methyl-11C]-D-methionie, 18F-
-FDS, 18F-fluoromaltose and 18F-fluoromaltohexaose 
are one of the most recent radiopharmaceuticals used 
in PET/CT studies for imaging bacterial infections. 
MAb (1D9) against Staphylococcus antigen A or 
a gram-positive bacterium has been recently labeled 
with a copper 64 isotope (64Cu, T1/2 = 12.7 h) and 
zirconium 89 (89Zr, T1/2 = 78.4 h) and evaluated in PET 
on mice. MAb 1D9 clearly targeted S. aureus on the 3rd 
day after the radiotracer injection, the ratio of abscess 
to background was 2–3 times higher than in control 
groups and comparable to the results obtained from 
the 18F-FDG-PET study. MAb 1D9 also showed nonspe-
cific uptake in E. coli infections and lipopolysaccharide-
-induced sterile inflammations, attributed to the bind-
ing of MAb to Fc receptors present in the membrane 
of the cell-infiltrating macrophages [36–38].
Trimethoprim (TMP) is an organic chemical com-
pound, a chemotherapeutic agent that inhibits bacterial 
dihydrofolic acid reductase, an enzyme in the synthe-
sis of DNA and the folate pathway of most bacterial 
species (including Gram-positive and Gram-negative), 
mycobacteria and some parasites. As a PET radiotracer, 
18F-fluoropropylotrimethoprim (18F-FPTMP) showed 
a high uptake in bacteria, in in vitro studies performed 
in mice and a high ratio of abscesses to muscles, which 
ranged between 2 and 3 in mice. However, due to the 
high activity in the liver, gallbladder and intestines, 
imaging of infections in the abdomen appears to be 
limited [39].
Antimicrobial peptides (AMP) designed to quickly 
kill a wide spectrum of pathogens, including Gram-
-positive and Gram-negative bacteria, fungi, parasites 
and even capsular viruses. UBI29–41 most commonly 
labelled with 99mTc, is a cationic synthetic particle de-
rived from natural cationic vicbuicidin AMP (UBI1–59) 
however, recently this ligand has been used for PET/CT 
studies in combination with 68Ga. Both PET analogues 
68Ga-NOTA-UBI29–41 and 
68Ga-NOTA-UBI31–38 showed 
comparable characteristics of uptake in infected femo-
ral muscles in mice and rabbits. However UBI29–41 was 
also accumulated in yeast-induced infections, which 
reduces the specificity of the use of this marker to 
visualize only the bacterial infections [40, 41].
PET with a radiofluorinated analogue of p-amino-
benzoic acid m-[18F]-fluoro-PABA, which is a substrate 
for the synthesis of folic acid in prokaryotic organisms, 
was performed on rats infected with methicillin or 
staphylococcus aureus. PET study with m-[18F]-fluoro-
PABA showed rapid uptake in bacterial infections (core 
to muscle ratio ≈ 8) and low uptake in sterile inflam-
mation (about nine times lower), which meant that 
this radiopharmaceutical can be considered as specific 
for imaging bacterial infections. m-[18F]-fluoro-PABA 
showed reduced uptake in tissues infected with Staphy-
lococcus aureus treated with oxacillin, indicating the 
possibility of using this radiopharmaceutical also to 
monitor response to treatment [42].
Another substrate associated with the folic acid 
synthesis pathway is methionine, which has been 
studied in the context of Staphylococcus aureus and E. 
coli infection imaging. Based on the uptake in infected 
muscles in mice, a PET study with carbon-labeled (11C) 
methyl-D-methionine was helpful in differentiating 
(at 6–9 times higher abscess to inflammation ratios) 
between active non-active E. coli and staphylococcus 
infection [43]. 
Siderophores, low molecular weight iron transpor-
ters, are used by most bacteria, fungi and some plants 
to remove iron from the environment, which is key 
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because of many different metabolic processes. In PET 
studies siderophores are usually labelled with 68Ga. An 
in vivo study with 68Ga-labeled triacetylfusarinine (68Ga-
-TAFC) performed on rats infected with A. fumigatus 
(Aspiroplasma), S. aureus and sterile inflammation in 
the thigh and lung muscles infection, showed increased 
radiotracer accumulation in A. fumigatus infected sites 
(ratio abscess to the background between 5.8 and 6.6). 
At the same time, there was also an increased uptake of 
the radiotracer in sterile inflammatory sites (although 
lower than in the case of A. fumigatus), while in tis-
sues infected with S. aureus, no 68Ga-TAFC uptake was 
observed [44].
In the imaging of bacterial infections, [18F]-fluoro-
sorbitol is also used (18F-FDS), sorbitol analogue, which 
is a substrate metabolized only by enterobacteria. It 
has been proven that 18F-FDS-PET imaging is a promis-
ing diagnostic tool which helps to differentiate E. coli 
infections or a pneumonitis bacillus (K. pneumoniae) 
with Gram-positive infection. E. coli infections can be 
adequately visualized with 18F-FDS in mice, with uptake 
in infected tissues is about eight times higher than 
sterile inflammation. Additionally, 18F-FDS-PET after 
ceftriaxone antimicrobial therapy in E. coli infection 
showed that in infected tissues, radiotracer uptake is 
eight-fold lower for those treated with ceftriaxone. 
This showed that 18F-FDS can be used in antimicrobial 
therapy monitoring [45].
Type 1 diabetes is characterized by the loss of 
b-cells in the islets of the pancreatic Langerhans, fol-
lowed by a deficiency of insulin secretion in response 
to hyperglycaemia. The development of an in vivo test 
that would allow the assessment of b-cell mass (BCM) 
mass measurement would significantly increase the 
ability to track diabetes therapy. The b-cells and neu-
rological tissues share common cellular receptors and 
transporters, therefore a study using brain radioligands 
for their ability to identify b-cells has been performed. 
The D2/D3 receptor agonist, radioligand 11C-(+)-propyl-
hexahydro-naphthooxazin (11C-PHNO) was the only one 
showing high uptake in the pancreas with respect to 
the abdominal organs, such as the kidneys, liver and 
spleen. However, further in vitro and in vivo studies 
to determine the specificity of the D3 receptor for 
b-cells are indicated to introduce 11C-PHNO as a specific 
radiotracer used to measure BCM [46]. 
One of the most advantages of imaging in nuclear 
medicine is that it allows imaging of functional changes 
which usually occur much earlier than anatomical 
changes that can be visualized by standard imaging 
methods. All the new methods which are in the clinical 
trial phase, if will be approved for clinical use, might 
allow in earlier detection of changes, especially in the 
diagnosis of infection in diabetics, and thus less dia-
betic complications and better care for patients. Also 
early detection of changes which may suggest future 
diabetes development by using nuclear imaging mo-
dalities, will allow close control and better care of this 
group of patients.
Conclusion
Nuclear medicine plays a significant role in the 
diagnosis of infection and other diseases occurring in 
diabetic patients. The use of proper radiopharmaceuti-
cals obtain accurate location and diagnosis of diseases, 
and the combination of nuclear medicine techniques 
with commonly used imaging methods in diabetic 
patients permits the implementation of appropriate 
treatment and its control.
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